Interpace Biosciences, Inc. (IDXG): Price and Financial Metrics

Interpace Biosciences, Inc. (IDXG): $1.65

0.00 (0.00%)

POWR Rating

Component Grades













IDXG Stock Summary

  • INTERPACE BIOSCIENCES INC's market capitalization of $6,794,075 is ahead of only 1.95% of US-listed equities.
  • INTERPACE BIOSCIENCES INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 5.22% of US listed stocks.
  • IDXG's price/sales ratio is 0.17; that's higher than the P/S ratio of only 4.08% of US stocks.
  • If you're looking for stocks that are quantitatively similar to INTERPACE BIOSCIENCES INC, a group of peers worth examining would be TOMZ, ANGI, IAC, TCMD, and RKDA.
  • Visit IDXG's SEC page to see the company's official filings. To visit the company's web site, go to

IDXG Valuation Summary

  • IDXG's price/sales ratio is 0.2; this is 89.47% lower than that of the median Healthcare stock.
  • Over the past 243 months, IDXG's price/sales ratio has gone down 0.

Below are key valuation metrics over time for IDXG.

Stock Date P/S P/B P/E EV/EBIT
IDXG 2022-11-01 0.2 -0.2 -0.6 -1.5
IDXG 2022-10-31 0.2 -0.2 -0.5 -1.5
IDXG 2022-10-28 0.2 -0.2 -0.6 -1.5
IDXG 2022-10-27 0.2 -0.2 -0.6 -1.5
IDXG 2022-10-26 0.2 -0.2 -0.5 -1.5
IDXG 2022-10-25 0.2 -0.2 -0.6 -1.5

IDXG Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 58.13%.
  • Its 4 year revenue growth rate is now at 108.4%.
  • The 3 year revenue growth rate now stands at 81.21%.
IDXG's revenue has moved up $15,974,000 over the prior 30 months.

The table below shows IDXG's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 40.053 -6.066 -13.476
2022-03-31 41.857 -4.967 -12.983
2021-12-31 41.314 -8.719 -14.943
2021-09-30 40.106 -9.085 -19.357
2021-09-30 40.106 -9.085 -19.357
2021-06-30 38.882 -14.131 -22.03

IDXG Price Target

For more insight on analysts targets of IDXG, see our IDXG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.43 Average Broker Recommendation 1.5 (Moderate Buy)

IDXG Stock Price Chart Interactive Chart >

Price chart for IDXG

IDXG Price/Volume Stats

Current price $1.65 52-week high $9.00
Prev. close $1.65 52-week low $1.05
Day low $1.65 Volume 300
Day high $1.65 Avg. volume 8,082
50-day MA $1.82 Dividend yield N/A
200-day MA $3.28 Market Cap 7.01M

Interpace Biosciences, Inc. (IDXG) Company Bio

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

IDXG Latest News Stream

Event/Time News Detail
Loading, please wait...

IDXG Latest Social Stream

Loading social stream, please wait...

View Full IDXG Social Stream

Latest IDXG News From Around the Web

Below are the latest news stories about INTERPACE BIOSCIENCES INC that investors may wish to consider to help them evaluate IDXG as an investment opportunity.

Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced new clinical validation data for their thyroid cancer test platform which is comprised of a mutation panel (ThyGeNEXT®) and a microRNA (miRNA) risk classifier. The new data demonstrates that

Yahoo | September 1, 2022

Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.

Interpace Transitions to focused Molecular Diagnostics BusinessDisposition of Pharma Services Expected to Improve Operating Cash Flow by nearly $5 million Annually PARSIPPANY, NJ, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced the closing of a definitive asset purchase agreement under which Flagship Biosciences, Inc. has acquired the Company’s Pharma Services business (Interpace

Yahoo | August 31, 2022

Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

●Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® ●2022 Year to Date Net Loss Improves by $1.5 million ●Days Sales Outstanding (DSO) decreased by 15% PARSIPPANY, NJ, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2022 and provided a business and financial update. Second quarter Net Revenue was $9.

Yahoo | August 15, 2022

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Interpace Diagnostics Group (OtherIDXG), Kamada (KMDA) and Galmed Pharmaceuticals (GLMD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Interpace Diagnostics Group (IDXG – Research Report), Kamada (KMDA – Research Report) and Galmed Pharmaceuticals (GLMD – Research Report). Interpace Diagnostics Group (IDXG) H.C. Wainwright analyst Yi Chen reiterated a Hold rating on Interpace Diagnostics Group today. The company's shares closed last Tuesday at $3.46, close to its 52-week low of $2.76. According to, Chen 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.7% and a 27.7% success rate.

Catie Powers on TipRanks | May 18, 2022

Interpace Biosciences Announces First Quarter 2022 Financial and Business Results

●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6% increase as compared to the same period of 2021. Our N

Yahoo | May 16, 2022

Read More 'IDXG' Stories Here

IDXG Price Returns

1-mo -8.59%
3-mo -12.70%
6-mo N/A
1-year -77.47%
3-year -62.04%
5-year -85.00%
YTD -77.91%
2021 137.90%
2020 -37.20%
2019 -37.50%
2018 -21.57%
2017 -76.82%

Continue Researching IDXG

Want to see what other sources are saying about Interpace Biosciences Inc's financials and stock price? Try the links below:

Interpace Biosciences Inc (IDXG) Stock Price | Nasdaq
Interpace Biosciences Inc (IDXG) Stock Quote, History and News - Yahoo Finance
Interpace Biosciences Inc (IDXG) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7697 seconds.